stomach paralysis semaglutide Ozempic Delayed Gastric Emptying Led to Paralysis: Lawsuit Companies making Ozempic and Mounjaro

That's not a reason to dismiss the product

No self-medication: Avoid starting or stopping any treatment without the supervision of a health professional

S1102 GLP-1 Receptor Agonist Use for Reducing Symptom Burden and Medication Utilization in Non-Obese Women With IBS-D: A Propensity Matched Retrospective Cohort Study

CC - central canal

Safety Profile The most common adverse events documented across retatrutide results data were gastrointestinal in nature, with incidence increasing at higher doses: Nausea: 6-31% (dose-dependent), primarily during escalation periods Diarrhea: 6-25%, generally mild to moderate Vomiting: 0-16%, occurring mainly in the first weeks of each dose increase Decreased appetite: 3-19%, which contributed to the weight reduction effect Constipation: 3-12%, consistent with GLP-1 receptor-mediated gastric slowing Serious adverse events were rare across all cohorts

The most significant concern involves systemic infection (bacteremia or fungemia) in immunocompromised patients, though this remains rare with quality-controlled products